{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:51:37Z","timestamp":1791921097059,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07446-9","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:36:54Z","timestamp":1790347014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reserve antibiotics in paediatrics: single-centre clinical experience and antimicrobial stewardship implementation"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0340-6489","authenticated-orcid":false,"given":"Marta","family":"Ech\u00e1varri de Miguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0418-3391","authenticated-orcid":false,"given":"Lola","family":"Bernab\u00e9u Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6096-7121","authenticated-orcid":false,"given":"Andrea","family":"S\u00e1nchez Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4949-9322","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Riva de la Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6194-7180","authenticated-orcid":false,"given":"Mercedes","family":"Gil Arregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8405-873X","authenticated-orcid":false,"given":"Francisco Jos\u00e9","family":"Collado D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7051-1497","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-1319","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Gonz\u00e1lez Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-2182","authenticated-orcid":false,"given":"Marta Taida","family":"Garc\u00eda Ascaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-6621","authenticated-orcid":false,"given":"Margarita","family":"Cuervas-Mons Vendrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"10459","key":"7446_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE et al (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404(10459):1199\u20131226. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1","journal-title":"Lancet"},{"issue":"10325","key":"7446_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399(10325):629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"7446_CR3","unstructured":"World Health Organization (2024) 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis. https:\/\/www.who.int\/publications\/i\/item\/9789240094000. Accessed 11 Mar 2026"},{"key":"7446_CR4","unstructured":"World Health Organization (2026) WHO antibiotics categorization. https:\/\/aware.essentialmeds.org\/list. Accessed 11 Mar 2026"},{"key":"7446_CR5","unstructured":"Ram\u00edrez-Gil J, Valero-Cervera E, P\u00e9rez-Cebri\u00e1n M, Buigues-Pastor L, Valenzuela-M\u00e9ndez A, Puig-Ferrer M (2023) Informaci\u00f3n farmacoterap\u00e9utica de la Comunitat Valenciana. Resistencias a antibi\u00f3ticos: Clasificaci\u00f3n AWaRe de la OMS. Valencia: Direcci\u00f3n General de Farmacia, Generalitat Valenciana. https:\/\/www.san.gva.es\/documents\/d\/farmacia-i-productes-sanitaris\/boletin-farmacoterapeutico-9-aware-oms. Accessed 11 Mar 2026"},{"key":"7446_CR6","unstructured":"Centers for Disease Control and Prevention (2025) Antibiotic prescribing and use: core elements of hospital antibiotic stewardship programs. https:\/\/www.cdc.gov\/antibiotic-use\/hcp\/core-elements\/hospital.html. Accessed 12 Mar 2026"},{"key":"7446_CR7","unstructured":"Joint Commission (2026) What are the leadership and monitoring expectations for a hospital\u2019s antibiotic stewardship program? https:\/\/www.jointcommission.org\/en-us\/knowledge-library\/support-center\/standards-interpretation\/standards-faqs\/000002449. Accessed 12 Mar 2026"},{"key":"7446_CR8","unstructured":"Federal Register (2019) Medicare and Medicaid Programs; Hospital and Critical Access Hospital (CAH) changes to promote innovation, flexibility, and improvement in patient care; extension of timeline for publication of the final rule. https:\/\/www.federalregister.gov\/documents\/2019\/06\/11\/2019-12216\/medicare-and-medicaid-programs-hospital-and-critical-access-hospital-cah-changes-to-promote. Accessed 12 Mar\u00a0 2026"},{"key":"7446_CR9","unstructured":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria (2016) Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos. https:\/\/gruposdetrabajo.sefh.es\/genesis\/genesis\/Documents\/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdf. Accessed 12 Mar 2026"},{"issue":"4","key":"7446_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40272-025-00685-7","volume":"27","author":"A Castro-Fronti\u00f1\u00e1n","year":"2025","unstructured":"Castro-Fronti\u00f1\u00e1n A, Prieto-Tato LM, Caro-Teller JM, Epalza C, Gonz\u00e1lez-G\u00f3mez \u00c1, Villaverde S, Shan-N\u00fa\u00f1ez A, Viedma E, Ferrari-Piquero JM (2025) Ceftazidime\/avibactam for the treatment of infections in children: a case series of real-world use. Paediatr Drugs 27(4):427\u2013438. https:\/\/doi.org\/10.1007\/s40272-025-00685-7","journal-title":"Paediatr Drugs"},{"issue":"1","key":"7446_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jpids\/piz085","volume":"9","author":"K Chiotos","year":"2020","unstructured":"Chiotos K, Hayes M, Gerber JS, Tamma PD (2020) Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatr Infect Dis Soc 9(1):56\u201366. https:\/\/doi.org\/10.1093\/jpids\/piz085","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"10","key":"7446_CR12","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.1128\/AAC.00862-16","volume":"60","author":"JS Bradley","year":"2016","unstructured":"Bradley JS, Armstrong J, Arrieta A, Bishai R, Das S, Delair S et al (2016) Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients. Antimicrob Agents Chemother 60(10):6252\u20136259. https:\/\/doi.org\/10.1128\/AAC.00862-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"7446_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/INF.0000000000002395","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, Roilides E, Broadhurst H, Cheng K, Huang LM, MasCasullo V et al (2019) Safety and efficacy of ceftazidime-avibactam in children \u22653 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial. Pediatr Infect Dis J 38(9):920\u2013928. https:\/\/doi.org\/10.1097\/INF.0000000000002395","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"7446_CR14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/INF.0000000000002392","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M et al (2019) Safety and efficacy of ceftazidime-avibactam plus metronidazole in children \u22653 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial. Pediatr Infect Dis J 38(8):816\u2013824. https:\/\/doi.org\/10.1097\/INF.0000000000002392","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"7446_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02578-18","volume":"63","author":"KB Larson","year":"2019","unstructured":"Larson KB, Patel YT, Willavize S, Bradley JS, Rhee EG, Caro L, Rizk ML (2019) Ceftolozane-tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intra-abdominal infections. Antimicrob Agents Chemother 63(6):e02578-18. https:\/\/doi.org\/10.1128\/AAC.02578-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"7446_CR16","doi-asserted-by":"publisher","first-page":"S528","DOI":"10.1093\/ofid\/ofx163.1376","volume":"4","author":"K Larson","year":"2017","unstructured":"Larson K, Johnson MG, Rizk ML, Caro L, Bradley JS, Ang J, Rhee E (2017) Ceftolozane\/tazobactam dose evaluation for pediatric subjects with complicated intra-abdominal infection and complicated urinary tract infection. Open Forum Infect Dis 4(1):S528-529. https:\/\/doi.org\/10.1093\/ofid\/ofx163.1376","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"7446_CR17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/INF.0000000000001159","volume":"35","author":"CR Cannavino","year":"2016","unstructured":"Cannavino CR, Nemeth A, Korczowski B, Bradley JS, O\u2019Neal T, Jandourek A, Friedland HD, Kaplan SL (2016) A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone. Pediatr Infect Dis J 35(7):752\u2013759. https:\/\/doi.org\/10.1097\/INF.0000000000001159","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"7446_CR18","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","volume":"35","author":"B Korczowski","year":"2016","unstructured":"Korczowski B, Antadze T, Giorgobiani M, Stryjewski ME, Jandourek A, Smith A, O\u2019Neal T, Bradley JS (2016) A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection. Pediatr Infect Dis J 35(8):e239-247. https:\/\/doi.org\/10.1097\/INF.0000000000001191","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"7446_CR19","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","volume":"73","author":"NC Warner","year":"2021","unstructured":"Warner NC, Bartelt LA, Lachiewicz AM, Tompkins KM, Miller MB, Alby K et al (2021) Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections. Clin Infect Dis 73(7):e1754\u2013e1757. https:\/\/doi.org\/10.1093\/cid\/ciaa1847","journal-title":"Clin Infect Dis"},{"issue":"3","key":"7446_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12098-022-04468-7","volume":"90","author":"S Bawankule","year":"2023","unstructured":"Bawankule S, Nabar N, Joshi P, Singhal T (2023) Cefiderocol as salvage therapy for carbapenem-resistant Klebsiella pneumoniae sepsis in an extremely preterm neonate. Indian J Pediatr 90(3):310. https:\/\/doi.org\/10.1007\/s12098-022-04468-7","journal-title":"Indian J Pediatr"},{"issue":"2","key":"7446_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2025.104515","volume":"29","author":"WT Hoshino","year":"2025","unstructured":"Hoshino WT, da Silva AMPDS, Pignatari AC, Gales AC, Carlesse F (2025) Experience with ceftazidime-avibactam for MDR BGN infection in oncologic children. Braz J Infect Dis 29(2):104515. https:\/\/doi.org\/10.1016\/j.bjid.2025.104515","journal-title":"Braz J Infect Dis"},{"issue":"7","key":"7446_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/INF.0000000000004768","volume":"44","author":"P Lab\u00e9","year":"2025","unstructured":"Lab\u00e9 P, Husain M, Parize P, Grimaud M, Roy C, Ratiney R, Cohen JF, Lecuyer H, Toubiana J (2025) Evaluation of ceftazidime-avibactam and ceftolozane-tazobactam prescriptions in a tertiary hospital for children in France: an observational study, 2017\u20132022. Pediatr Infect Dis J 44(7):630\u2013636. https:\/\/doi.org\/10.1097\/INF.0000000000004768","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"7446_CR23","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10096-024-04948-y","volume":"43","author":"OO Gundeslioglu","year":"2024","unstructured":"Gundeslioglu OO, Haytoglu Z, Gumus HH, Ekinci F, Kibar F, Cay U, Alabaz D, Ozlu F, Horoz OO, Y\u0131ld\u0131zdas RD (2024) Clinical experience with ceftazidime\/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children. Eur J Clin Microbiol Infect Dis 43(12):2361\u20132369. https:\/\/doi.org\/10.1007\/s10096-024-04948-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"7446_CR24","doi-asserted-by":"crossref","unstructured":"Tamma PD, Bonomo RA, Heil EL, Justo JA, Satlin MJ, Mathers AJ (2026) IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Infectious Diseases Society of America. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/. Accessed 6 Sept 2026.","DOI":"10.1093\/cid\/ciag481"},{"issue":"4","key":"7446_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA et al (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect 28(4):521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"7446_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaf004","volume":"14","author":"CR Lockowitz","year":"2025","unstructured":"Lockowitz CR, Hsu AJ, Chiotos K, Bio LL, Dassner AM, Gainey AB et al (2025) Suggested dosing of select beta-lactam agents for the treatment of antimicrobial-resistant Gram-negative infections in children. J Pediatric Infect Dis Soc 14(2):piaf004. https:\/\/doi.org\/10.1093\/jpids\/piaf004","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"9","key":"7446_CR27","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/INF.0000000000001228","volume":"35","author":"SL Aitken","year":"2016","unstructured":"Aitken SL, Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, Nicolau DP, Nunez CA (2016) Use of ceftolozane\/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient. Pediatr Infect Dis J 35(9):1040\u20131042. https:\/\/doi.org\/10.1097\/INF.0000000000001228","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"7446_CR28","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1128\/AAC.00705-16","volume":"60","author":"JY Ang","year":"2016","unstructured":"Ang JY, Abdel-Haq N, Zhu F, Thabit AK, Nicolau DP, Satlin MJ, van Duin D (2016) Multidrug-resistant Pseudomonas aeruginosa infection in a child with cystic fibrosis. Antimicrob Agents Chemother 60(10):5627\u20135630. https:\/\/doi.org\/10.1128\/AAC.00705-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"7446_CR29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/jpc.14388","volume":"55","author":"M Mart\u00edn-Caza\u00f1a","year":"2019","unstructured":"Mart\u00edn-Caza\u00f1a M, Grau S, Epalza C, Bra\u00f1as P, Flores M, Olmedilla M, Bl\u00e1zquez-Gamero D (2019) Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa. J Paediatr Child Health 55(8):985\u2013987. https:\/\/doi.org\/10.1111\/jpc.14388","journal-title":"J Paediatr Child Health"},{"issue":"5","key":"7446_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/INF.0000000000002593","volume":"39","author":"L Molloy","year":"2020","unstructured":"Molloy L, Abdulhamid I, Srivastava R, Ang JY (2020) Ceftolozane\/tazobactam treatment of multidrug-resistant Pseudomonas aeruginosa infections in children. Pediatr Infect Dis J 39(5):419\u2013420. https:\/\/doi.org\/10.1097\/INF.0000000000002593","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"7446_CR31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","volume":"49","author":"A Dinh","year":"2017","unstructured":"Dinh A, Wyplosz B, Kern\u00e9is S, Lebeaux D, Bouchand F, Duran C et al (2017) Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 49(6):782\u2013783. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.04.001","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"7446_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/antibiotics8020067","volume":"8","author":"A Zikri","year":"2019","unstructured":"Zikri A, El Masri K (2019) Use of ceftolozane\/tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a pediatric patient with combined immunodeficiency (CID): a case report from a tertiary hospital in Saudi Arabia. Antibiotics 8(2):67. https:\/\/doi.org\/10.3390\/antibiotics8020067","journal-title":"Antibiotics"},{"issue":"11","key":"7446_CR33","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/ppul.24945","volume":"55","author":"AB Gainey","year":"2020","unstructured":"Gainey AB, Burch AK, Brownstein MJ, Brown DE, Fackler J, Horne B, Biswas B, Bivens BN, Malagon F, Daniels R (2020) Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol 55(11):2990\u20132994. https:\/\/doi.org\/10.1002\/ppul.24945","journal-title":"Pediatr Pulmonol"},{"key":"7446_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jgar.2021.04.025","volume":"26","author":"CD Grasa","year":"2021","unstructured":"Grasa CD, G\u00f3mez-Gil MR, San Rom\u00e1n Pacheco S, Del Rosal T, Moreno F, Gerig N, Ochoa Fern\u00e1ndez B, Calvo C, Baquero-Artigao F (2021) Compassionate use of cefiderocol for VIM metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma. J Glob Antimicrob Resist 26:91\u201392. https:\/\/doi.org\/10.1016\/j.jgar.2021.04.025","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"7446_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40121-022-00735-4","volume":"12","author":"C Monari","year":"2023","unstructured":"Monari C, Spagnuolo F, Pisaturo M, Ascione S, Donnarumma G, Cal\u00f2 F et al (2023) Bloodstream infection due to a VIM-metallo-\u03b2-lactamase-producing Klebsiella pneumoniae treated with cefiderocol in a preterm newborn. Infect Dis Ther 12(2):727\u2013734. https:\/\/doi.org\/10.1007\/s40121-022-00735-4","journal-title":"Infect Dis Ther"},{"issue":"2","key":"7446_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/INF.0000000000004150","volume":"43","author":"K Shapiro","year":"2024","unstructured":"Shapiro K, Ungar SP, Krugman J, McGarrity O, Cross SJ, Indrakumar B, Hatcher J, Ratner A, Wolf J (2024) Cefiderocol red wine urine syndrome in pediatric patients: a multicenter case series. Pediatr Infect Dis J 43(2):142\u2013144. https:\/\/doi.org\/10.1097\/INF.0000000000004150","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"7446_CR37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/INF.0000000000004347","volume":"43","author":"H Schmid","year":"2024","unstructured":"Schmid H, Brown LAK, Indrakumar B, McGarrity O, Hatcher J, Bamford A (2024) Use of cefiderocol in the management of children with infection or colonization with multidrug-resistant Gram-negative bacteria: a retrospective, single-center case series. Pediatr Infect Dis J 43(8):772\u2013776. https:\/\/doi.org\/10.1097\/INF.0000000000004347","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"7446_CR38","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1093\/jac\/dkad277","volume":"78","author":"E Funiciello","year":"2023","unstructured":"Funiciello E, Mula J, Mignone F, Silvestro E, Ragazzi P, Pilloni G, Costa C, D\u2019Avolio A, Garazzino S (2023) Plasmatic and CSF concentrations of cefiderocol in an infant with extensively drug-resistant Pseudomonas aeruginosa meningoencephalitis. J Antimicrob Chemother 78(11):2776\u20132778. https:\/\/doi.org\/10.1093\/jac\/dkad277","journal-title":"J Antimicrob Chemother"},{"key":"7446_CR39","doi-asserted-by":"publisher","unstructured":"Hsu AJ, Simner PJ, Bergman Y, Mathers AJ, Tamma PD (2023) Successful treatment of persistent Stenotrophomonas maltophilia bacteremia with cefiderocol in an infant. Open Forum Infect Dis 10(4):ofad174. https:\/\/doi.org\/10.1093\/ofid\/ofad174","DOI":"10.1093\/ofid\/ofad174"},{"issue":"1","key":"7446_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/antibiotics13010037","volume":"13","author":"S Mercadante","year":"2023","unstructured":"Mercadante S, Tripiciano C, Romani L, Di Nardo M, Bottari G, Goffredo BM et al (2023) The use of cefiderocol as salvage therapy in an infant receiving ECMO and continuous renal replacement therapy. Antibiotics 13(1):37. https:\/\/doi.org\/10.3390\/antibiotics13010037","journal-title":"Antibiotics"},{"issue":"4","key":"7446_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2024.116539","volume":"110","author":"J A\u00f1\u00f3n-Hidalgo","year":"2024","unstructured":"A\u00f1\u00f3n-Hidalgo J, Garrido-Rodr\u00edguez M, Gonz\u00e1lez-Abad MJ, Cuervas-Mons Vendrell M, Garc\u00eda-Ascaso MT, D\u00edaz P\u00e9rez D, Garc\u00eda-Salido A (2024) Cefiderocol as rescue therapy in a cancer immunosuppressed critically ill child: case description and literature review. Diagn Microbiol Infect Dis 110(4):116539. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116539","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"7446_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.5863\/1551-6776-20.6.476","volume":"20","author":"AW Williams","year":"2015","unstructured":"Williams AW, Newman PM, Ocheltree S, Beaty R, Hassoun A (2015) Ceftaroline fosamil use in 2 pediatric patients with invasive methicillin-resistant Staphylococcus aureus infections. J Pediatr Pharmacol Ther 20(6):476\u2013480. https:\/\/doi.org\/10.5863\/1551-6776-20.6.476","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"7446_CR43","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1097\/PCC.0000000000001497","volume":"19","author":"JJ Cies","year":"2018","unstructured":"Cies JJ, Moore WS, Enache A, Chopra A (2018) Ceftaroline for suspected or confirmed invasive methicillin-resistant Staphylococcus aureus: a pharmacokinetic case series. Pediatr Crit Care Med 19(6):e292\u2013e299. https:\/\/doi.org\/10.1097\/PCC.0000000000001497","journal-title":"Pediatr Crit Care Med"},{"issue":"12","key":"7446_CR44","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1002\/ppul.25029","volume":"55","author":"J Branstetter","year":"2020","unstructured":"Branstetter J, Searcy H, Benner K, Yarbrough A, Crowder C, Troxler B (2020) Ceftaroline versus vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis. Pediatr Pulmonol 55(12):3337\u20133342. https:\/\/doi.org\/10.1002\/ppul.25029","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"7446_CR45","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/INF.0000000000004023","volume":"42","author":"A Callies","year":"2023","unstructured":"Callies A, Martin-Perceval L, Cr\u00e9met L, G\u00e9ly L, Ruellan AL, Verdier MC et al (2023) Safety and efficacy of ceftaroline in neonates with Staphylococcal late-onset sepsis: a case series analysis. Pediatr Infect Dis J 42(10):888\u2013892. https:\/\/doi.org\/10.1097\/INF.0000000000004023","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"7446_CR46","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/antibiotics14090864","volume":"14","author":"A Miller","year":"2025","unstructured":"Miller A, Grizzle M, Van Poppel H, Alvira-Arill GR, Lueking R, Thacker SA, Hornback KM, Morrissette T (2025) Evaluation of ceftaroline use in pediatric patients: a retrospective case series. Antibiotics 14(9):864. https:\/\/doi.org\/10.3390\/antibiotics14090864","journal-title":"Antibiotics"},{"key":"7446_CR47","doi-asserted-by":"publisher","unstructured":"Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM (2021) Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist 3(1):dlaa114. https:\/\/doi.org\/10.1093\/jacamr\/dlaa114.","DOI":"10.1093\/jacamr\/dlaa114"},{"issue":"1","key":"7446_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jpids\/piad089","volume":"13","author":"CR Woods","year":"2024","unstructured":"Woods CR, Bradley JS, Chatterjee A et al (2024) Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2023 guideline on diagnosis and management of acute bacterial arthritis in pediatrics. J Pediatric Infect Dis Soc 13(1):1\u201359","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"7446_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.anpedi.2012.07.005","volume":"78","author":"L Escosa-Garc\u00eda","year":"2013","unstructured":"Escosa-Garc\u00eda L, Ramilo O, Mej\u00edas A (2013) High-dose daptomycin use in methicillin-resistant Staphylococcus aureus disseminated infection. An Pediatr 78(3):185\u2013188. https:\/\/doi.org\/10.1016\/j.anpedi.2012.07.005","journal-title":"An Pediatr"},{"issue":"5","key":"7446_CR50","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/INF.0000000000001076","volume":"35","author":"V Syriopoulou","year":"2016","unstructured":"Syriopoulou V, Dailiana Z, Dmitriy N, Utili R, Pathan R, Hamed K (2016) Clinical experience with daptomycin for the treatment of Gram-positive infections in children and adolescents. Pediatr Infect Dis J 35(5):511\u2013516. https:\/\/doi.org\/10.1097\/INF.0000000000001076","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"7446_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/phar.1872","volume":"37","author":"KC Namtu","year":"2017","unstructured":"Namtu KC, Crain JC, Messina AF, Dumois JA, Berman DM (2017) Clinical experience with daptomycin in pediatrics. Pharmacotherapy 37(1):105\u2013108. https:\/\/doi.org\/10.1002\/phar.1872","journal-title":"Pharmacotherapy"},{"issue":"2","key":"7446_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/INF.0000000000000962","volume":"35","author":"S Tedeschi","year":"2016","unstructured":"Tedeschi S, Tumietto F, Conti M, Giannella M, Viale P (2016) Use of daptomycin in critically ill children with bloodstream infections and complicated skin and soft-tissue infections. Pediatr Infect Dis J 35(2):180\u2013182. https:\/\/doi.org\/10.1097\/INF.0000000000000962","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"7446_CR53","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/INF.0000000000001629","volume":"36","author":"GA Syrogiannopoulos","year":"2017","unstructured":"Syrogiannopoulos GA, Michoula AN, Petinaki E, Grivea IN (2017) Daptomycin use in children: experience with various types of infection and age groups. Pediatr Infect Dis J 36(10):962\u2013966. https:\/\/doi.org\/10.1097\/INF.0000000000001629","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"7446_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4067\/S0716-10182020000100019","volume":"37","author":"MT Rosanova","year":"2020","unstructured":"Rosanova MT, Sberna N, Sarkis C, Ruvinsky S, Berberian G, Bologna R (2020) Experience with daptomycin in a tertiary pediatric hospital. Rev Chil Infectol 37(1):19\u201322. https:\/\/doi.org\/10.4067\/S0716-10182020000100019","journal-title":"Rev Chil Infectol"},{"issue":"9","key":"7446_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13090833","volume":"13","author":"H Persha","year":"2024","unstructured":"Persha H, Thacker SA, Hornback KM, Alvira-Arill GR, Lueking R, Morrisette T (2024) Real-world clinical characteristics and outcomes with daptomycin use in pediatric patients: a retrospective case series. Antibiotics (Basel) 13(9):833. https:\/\/doi.org\/10.3390\/antibiotics13090833","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"7446_CR56","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1097\/INF.0000000000004804","volume":"44","author":"M Denina","year":"2025","unstructured":"Denina M, Abrate G, Silvestro E, Funiciello E, Pruccoli G, Sandei M, Mazzetti G, Garazzino S (2025) Daptomycin for pediatric complex bone and joint infections: real-world efficacy and safety data from a three-year study. Pediatr Infect Dis J 44(8):e291\u2013e295. https:\/\/doi.org\/10.1097\/INF.0000000000004804","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"7446_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0327993","volume":"20","author":"C Shiraishi","year":"2025","unstructured":"Shiraishi C, Kato H, Hirai J, Nishiyama N, Inagaki T, Ashizawa N et al (2025) Influence of renal function and daptomycin dose on clinical effectiveness and adverse events in Japanese pediatric patients: a multicenter retrospective observational study. PLoS ONE 20(7):e0327993. https:\/\/doi.org\/10.1371\/journal.pone.0327993","journal-title":"PLoS ONE"},{"issue":"1","key":"7446_CR58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/00099228241242186","volume":"64","author":"BJ Vonasek","year":"2025","unstructured":"Vonasek BJ, Samuel AM, Henderson SL, Strayer JR, Bogenschutz MC (2025) Safety and treatment outcomes of infants and children treated with daptomycin: six-year experience from a pediatric academic medical center. Clin Pediatr (Phila) 64(1):18\u201324. https:\/\/doi.org\/10.1177\/00099228241242186","journal-title":"Clin Pediatr (Phila)"},{"issue":"8","key":"7446_CR59","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/jpids\/piab027","volume":"10","author":"CR Woods","year":"2021","unstructured":"Woods CR, Bradley JS, Chatterjee A, Copley LA, Robinson J, Kronman MP et al (2021) Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. J Pediatric Infect Dis Soc 10(8):801\u2013844. https:\/\/doi.org\/10.1093\/jpids\/piab027","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"7446_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"LA Mermel","year":"2009","unstructured":"Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O\u2019Grady NP et al (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49(1):1\u201345. https:\/\/doi.org\/10.1086\/599376","journal-title":"Clin Infect Dis"},{"key":"7446_CR61","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) (2024) PROA Team Certification Standard \u2013 Hospital. https:\/\/resistenciaantibioticos.es\/sites\/default\/files\/2025-01\/PROA%20Team%20Certification%20Standard_Hospital.pdf. Accessed 12 Mar 2026"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07446-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:52Z","timestamp":1791920212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07446-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7446"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07446-9","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The observational component of this study was reviewed and approved by the Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n con medicamentos (CEIm) of the Hospital Infantil Universitario Ni\u00f1o Jes\u00fas (Madrid, Spain) (approval number: R-0086\/24). Informed consent was waived due to the retrospective nature of the study and use of anonymized data. The study was conducted in accordance with the Declaration of Helsinki and local data protection policies and data collection was carried out in accordance with national guidelines for retrospective research.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent to participate was waived by the CEIm as per national regulations (RD 957\/2020) due to the retrospective design of the study and the use of anonymized clinical data.Consent to publish is not applicable as no identifiable individual data, images, or personal information are included in this manuscript.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"776"}}